Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia

Bruce M. Camitta, Donald Pinkel, L. G. Thatcher, James Casper, Larry E. Kun, Stephen Lauer

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m2 IV weekly × 4) and Adriamycin (40 mg/m2 IV weeks 1 and 3). These drugs were not utilized during the induction or continuation phases of therapy. Treatment groups were similar with respect to patient age, sex, initial white cell count, and leukemic cell immunologic phenotype. Sixteen of 28 children who received the intensive phase of treatment relapsed, and one died in remission (pneumocystis pneumonia); 14/26 children who did not receive the intensive phase of treatment relapsed, and one died in remission (malignant histiocytosis). Times and sites of relapse were similar in both groups. Pneumocystis pneumonia (three cases) and herpes zoster (two cases) occurred only in children who received the intensive phase of treatment. In this study and in previously published reports, an early intensive phase of therapy did not improve prognosis in children with acute lymphocytic leukemia who also received three‐drug induction therapy, central nervous system prophylaxis, and continuation therapy with two or more agents.

Original languageEnglish (US)
Pages (from-to)383-389
Number of pages7
JournalMedical and Pediatric Oncology
Volume8
Issue number4
DOIs
StatePublished - Jan 1 1980

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Drug Therapy
Therapeutics
Pneumocystis Pneumonia
Histiocytic Sarcoma
Herpes Zoster
Doxorubicin
Cyclophosphamide
Central Nervous System
Cell Count
Phenotype
Recurrence

Keywords

  • acute lymphocytic leukemia
  • early intensive treatment

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. / Camitta, Bruce M.; Pinkel, Donald; Thatcher, L. G.; Casper, James; Kun, Larry E.; Lauer, Stephen.

In: Medical and Pediatric Oncology, Vol. 8, No. 4, 01.01.1980, p. 383-389.

Research output: Contribution to journalArticle

Camitta, Bruce M. ; Pinkel, Donald ; Thatcher, L. G. ; Casper, James ; Kun, Larry E. ; Lauer, Stephen. / Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia. In: Medical and Pediatric Oncology. 1980 ; Vol. 8, No. 4. pp. 383-389.
@article{0f8b550c92f247d693fce58df4ecf166,
title = "Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia",
abstract = "The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m2 IV weekly × 4) and Adriamycin (40 mg/m2 IV weeks 1 and 3). These drugs were not utilized during the induction or continuation phases of therapy. Treatment groups were similar with respect to patient age, sex, initial white cell count, and leukemic cell immunologic phenotype. Sixteen of 28 children who received the intensive phase of treatment relapsed, and one died in remission (pneumocystis pneumonia); 14/26 children who did not receive the intensive phase of treatment relapsed, and one died in remission (malignant histiocytosis). Times and sites of relapse were similar in both groups. Pneumocystis pneumonia (three cases) and herpes zoster (two cases) occurred only in children who received the intensive phase of treatment. In this study and in previously published reports, an early intensive phase of therapy did not improve prognosis in children with acute lymphocytic leukemia who also received three‐drug induction therapy, central nervous system prophylaxis, and continuation therapy with two or more agents.",
keywords = "acute lymphocytic leukemia, early intensive treatment",
author = "Camitta, {Bruce M.} and Donald Pinkel and Thatcher, {L. G.} and James Casper and Kun, {Larry E.} and Stephen Lauer",
year = "1980",
month = "1",
day = "1",
doi = "10.1002/mpo.2950080410",
language = "English (US)",
volume = "8",
pages = "383--389",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Failure of early intensive chemotherapy to improve prognosis in childhood acute lymphocytic leukemia

AU - Camitta, Bruce M.

AU - Pinkel, Donald

AU - Thatcher, L. G.

AU - Casper, James

AU - Kun, Larry E.

AU - Lauer, Stephen

PY - 1980/1/1

Y1 - 1980/1/1

N2 - The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m2 IV weekly × 4) and Adriamycin (40 mg/m2 IV weeks 1 and 3). These drugs were not utilized during the induction or continuation phases of therapy. Treatment groups were similar with respect to patient age, sex, initial white cell count, and leukemic cell immunologic phenotype. Sixteen of 28 children who received the intensive phase of treatment relapsed, and one died in remission (pneumocystis pneumonia); 14/26 children who did not receive the intensive phase of treatment relapsed, and one died in remission (malignant histiocytosis). Times and sites of relapse were similar in both groups. Pneumocystis pneumonia (three cases) and herpes zoster (two cases) occurred only in children who received the intensive phase of treatment. In this study and in previously published reports, an early intensive phase of therapy did not improve prognosis in children with acute lymphocytic leukemia who also received three‐drug induction therapy, central nervous system prophylaxis, and continuation therapy with two or more agents.

AB - The ability of intensive therapy, early in remission, to improve prognosis in childhood acute lymphocytic leukemia was tested in a randomized study. The intensive treatment included cyclophosphamide (200 mg/m2 IV weekly × 4) and Adriamycin (40 mg/m2 IV weeks 1 and 3). These drugs were not utilized during the induction or continuation phases of therapy. Treatment groups were similar with respect to patient age, sex, initial white cell count, and leukemic cell immunologic phenotype. Sixteen of 28 children who received the intensive phase of treatment relapsed, and one died in remission (pneumocystis pneumonia); 14/26 children who did not receive the intensive phase of treatment relapsed, and one died in remission (malignant histiocytosis). Times and sites of relapse were similar in both groups. Pneumocystis pneumonia (three cases) and herpes zoster (two cases) occurred only in children who received the intensive phase of treatment. In this study and in previously published reports, an early intensive phase of therapy did not improve prognosis in children with acute lymphocytic leukemia who also received three‐drug induction therapy, central nervous system prophylaxis, and continuation therapy with two or more agents.

KW - acute lymphocytic leukemia

KW - early intensive treatment

UR - http://www.scopus.com/inward/record.url?scp=0019277539&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019277539&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950080410

DO - 10.1002/mpo.2950080410

M3 - Article

C2 - 7005645

AN - SCOPUS:0019277539

VL - 8

SP - 383

EP - 389

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -